To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3350 | Mi-1900 |
Novel inhibitor of TMPRSS2, also strongly preventing SARS-CoV-2 multiplication and CPE in Calu-3 cells in a dose-dependent manner. causing strong inhibition of SARS-CoV-2 replication
More description
|
|
| DCC3349 | Mi-1061 |
Novel Chemically Stable, Potent, and Efficacious MDM2 Inhibitor
More description
|
|
| DCC3348 | Mhy884 |
Novel tyrosinase inhibitor, suppressing UVB-induced activation of NF-κB signaling pathway through the downregulation of oxidative stress
More description
|
|
| DCC3347 | mhy-794 |
Novel tyrosinase inhibitor, directly inhibiting mushroom tyrosinase
More description
|
|
| DCC3346 | mhy498 |
Novel inhibitor of nitric oxide-induced melanogenesis, targeting the NO-induced cGMP signaling pathway
More description
|
|
| DCC3345 | Mhy-449 |
Novel inducer of G2/M phase arrest in the cell cycle progression, resulting in growth inhibition and induction of apoptosis in a concentration-dependent manner, and inhibition of proliferation in a time-dependent manner
More description
|
|
| DCC3344 | mhy407 |
Novel sensitizer of cancer cells, significantly increasing DNA damage as determined by DNA breakage, levels of damage-responsive proteins, and DNA foci
More description
|
|
| DCC3343 | mhy384 |
Novel tyrosinase inhibitor, down-regulating of MITF and tyrosinase through direct tyrosinase inhibition
More description
|
|
| DCC3342 | mhy336 |
Novel topoisomerase II inhibitor, markedly inducing apoptotic cell death via the mitochondria-mediated intrinsic pathway in LNCaP cells
More description
|
|
| DCC3341 | Mhy219 |
Novel potent histone deacetylase (HDAC) inhibitor, inducing apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells
More description
|
|
| DCC3340 | mhy218 |
Novel potent HDAC inhibitor, possessing potent anticancer activities
More description
|
|
| DCC3339 | mhy1556 |
Novel tyrosinase inhibitor, showing concentration-dependent inhibitory effects with no significant cytotoxicity in cell viability assay
More description
|
|
| DCC3338 | Mhi-i2 |
Novel photodynamic antitumor agent
More description
|
|
| DCC3337 | Mhi-148 |
Near-infrared cyanine dye, acting as an optical imaging agent
More description
|
|
| DCC3336 | Mgs-0039 |
Potent and orally active group II mGluR antagonist with antidepressant-like potential
More description
|
|
| DCC3335 | Mgs-0028 |
Selective metabotropic glutamate 2/3 receptor agonist
More description
|
|
| DCC3334 | Mgcd516 |
Novel, multi-targeted kinase inhibitor, demonstrating potent inhibition of Trk, RET and DDR, in addition to Met, Axl and VEGFRs
More description
|
|
| DCC3331 | Mg2-1812 |
Novel potent negative allosteric modulator (NAM) of mGlu2
More description
|
|
| DCC3330 | Mfn103 |
Novel Dual Fluorescent and Magnetic Resonance False Neurotransmitter
More description
|
|
| DCC3329 | Metrizoate Calcium |
Radiographic Contrast Agent
More description
|
|
| DCC3328 | Metocurine |
Non-depolarizing muscle relaxant
More description
|
|
| DCC3327 | Metoclopramide Hydrochloride |
Dopamine D2 antagonist, antiemetic
More description
|
|
| DCC3326 | Met-in-3s |
Highly Selective Class II MET Inhibitor
More description
|
|
| DCC3325 | Methylnaltrexone Iodide |
Peripherally restricted μ-opioid antagonist
More description
|
|
| DCC3324 | Methylhonokiol |
Novel Class of Cannabinoid CB2 Receptor Inverse Agonist
More description
|
|
| DCC3323 | Methylene Quinuclidinone |
Metablite of PRIMA-1 and APR-246, covalently binding to cysteine residues in mutant p53 and wild type p53, and being increased in unfolded p53, inducing massive apoptosis in p53 null tumor cells
More description
|
|
| DCC3321 | Methyl Streptonigrin |
Novel inhibitor of ABCG2 transporter function
More description
|
|
| DCC3320 | Methyl Meso-(meta-pyridinium) Bodipy |
Novel photosensitizer as a photodynamic antimicrobial agent against Staphylococcus aureus, Escherichia coli, Candida albicans, and Methicillin-resistant S. aureus (MRSA)
More description
|
|
| DCC3319 | Methyl 6-bromo-1h-indazole-4-carboxylate |
Useful pharmaceutical building block
More description
|
|
| DCC3318 | Methoxyluteolin |
Inhibitor of pro-inflammatory mediator release from mast cells
More description
|
|